about-me variable
Julius Clinical invites you to their event

Scrutinizing Primary Endpoints in ALS Clinical Trials: ALSFRS-R, Survival or a Composite?

About this event

We are proud to present the webinar: Scrutinizing Primary Endpoints in ALS Clinical Trials: ALSFRS-R, Survival or a Composite?

During this live webinar, hosted by Thea Wesseling, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requirement of the EMA and FDA and statistical considerations.

They will touch upon:

  • Primary endpoints in ALS clinical trials
  • Regulatory requirements: differences between EMA and FDA
  • Statistical considerations for ALSFRS-R, survival and composites

Followed by a Q&A session.

Don't miss out and register now.

Hosted by

  • Guest speaker
    TW G
    Thea Wesseling Julius Clinical

  • Guest speaker
    G
    Stijn van Steenoven MsM @ Julius Clinical

  • Guest speaker
    Lv G
    Leonard van Den Berg TRICALS

  • Guest speaker
    Rv G
    Ruben van Eijk TRICALS

Julius Clinical

Julius Clinical is the Contract Research Organisation (CRO) that manages global clinical drug trials that will have a major impact on medicine and make a real difference to people’s lives around the world.